Q2 Earnings Estimate for BNTC Issued By HC Wainwright

Benitec Biopharma Limited (NASDAQ:BNTC) – HC Wainwright issued their Q2 2026 EPS estimates for Benitec Biopharma in a report released on Monday, November 24th. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will post earnings of ($0.24) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma’s Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.29) EPS.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.13.

BNTC has been the topic of several other research reports. Zacks Research raised Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research report on Friday, November 14th. JMP Securities set a $22.00 price objective on shares of Benitec Biopharma in a report on Tuesday, November 4th. Citizens Jmp increased their target price on shares of Benitec Biopharma from $20.00 to $22.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Benitec Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.33.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock opened at $12.93 on Tuesday. Benitec Biopharma has a 52 week low of $9.49 and a 52 week high of $17.15. The company has a quick ratio of 54.67, a current ratio of 54.67 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $14.37 and a 200-day moving average price of $13.71. The company has a market cap of $437.84 million, a PE ratio of -8.80 and a beta of 0.23.

Insider Activity at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 1,481,481 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The shares were bought at an average cost of $13.50 per share, with a total value of $19,999,993.50. Following the acquisition, the director owned 9,538,175 shares of the company’s stock, valued at $128,765,362.50. This represents a 18.39% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.80% of the stock is owned by insiders.

Institutional Trading of Benitec Biopharma

A number of large investors have recently added to or reduced their stakes in the stock. Police & Firemen s Retirement System of New Jersey bought a new stake in Benitec Biopharma in the second quarter worth about $38,000. BNP Paribas Financial Markets raised its holdings in shares of Benitec Biopharma by 44.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 904 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Benitec Biopharma in the 3rd quarter worth approximately $79,000. JPMorgan Chase & Co. purchased a new position in Benitec Biopharma in the second quarter valued at approximately $80,000. Finally, Bank of America Corp DE grew its holdings in Benitec Biopharma by 2,255.8% during the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,587 shares during the period. Hedge funds and other institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.